Vesikari T - Search Results

1

Immunogenicity and safety of rhesus-human rotavirus reassortant vaccines with serotype 1 or 2 VP7 specificity.

Vesikari T, Varis T, Green K, Flores J, Kapikian AZ. Vesikari T, et al. Vaccine. 1991 May;9(5):334-9. doi: 10.1016/0264-410x(91)90060-j. Vaccine. 1991. PMID: 1651610 Clinical Trial.

2

Neonatal administration of rhesus rotavirus tetravalent vaccine.

Vesikari T, Karvonen A, Forrest BD, Hoshino Y, Chanock RM, Kapikian AZ. Vesikari T, et al. Pediatr Infect Dis J. 2006 Feb;25(2):118-22. doi: 10.1097/01.inf.0000199288.98370.71. Pediatr Infect Dis J. 2006. PMID: 16462287 Clinical Trial.

3

Safety, efficacy, and immunogenicity of 2 doses of bovine-human (UK) and rhesus-rhesus-human rotavirus reassortant tetravalent vaccines in Finnish children.

Vesikari T, Karvonen AV, Majuri J, Zeng SQ, Pang XL, Kohberger R, Forrest BD, Hoshino Y, Chanock RM, Kapikian AZ. Vesikari T, et al. J Infect Dis. 2006 Aug 1;194(3):370-6. doi: 10.1086/505151. Epub 2006 Jun 23. J Infect Dis. 2006. PMID: 16826486 Clinical Trial.

4

Rotaviruses detected by reverse transcription polymerase chain reaction in acute gastroenteritis during a trial of rhesus-human reassortant rotavirus tetravalent vaccine: implications for vaccine efficacy analysis.

Pang XL, Joensuu J, Hoshino Y, Kapikian AZ, Vesikari T. Pang XL, et al. Among authors: vesikari t. J Clin Virol. 1999 Jun;13(1-2):9-16. doi: 10.1016/s1386-6532(98)00013-4. J Clin Virol. 1999. PMID: 10405887 Clinical Trial.

5

Protective efficacy against serotype 1 rotavirus diarrhea by live oral rhesus-human reassortant rotavirus vaccines with human rotavirus VP7 serotype 1 or 2 specificity.

Vesikari T, Ruuska T, Green KY, Flores J, Kapikian AZ. Vesikari T, et al. Pediatr Infect Dis J. 1992 Jul;11(7):535-42. doi: 10.1097/00006454-199207000-00006. Pediatr Infect Dis J. 1992. PMID: 1326741 Clinical Trial.

6

Evaluation of the M37 human rotavirus vaccine in 2- to 6-month-old infants.

Vesikari T, Ruuska T, Koivu HP, Green KY, Flores J, Kapikian AZ. Vesikari T, et al. Pediatr Infect Dis J. 1991 Dec;10(12):912-7. doi: 10.1097/00006454-199112000-00006. Pediatr Infect Dis J. 1991. PMID: 1662796 Clinical Trial.

7

Rhesus Rotavirus candidate vaccine. Clinical trial in children vaccinated between 2 and 5 months of age.

Vesikari T, Rautanen T, Varis T, Beards GM, Kapikian AZ. Vesikari T, et al. Am J Dis Child. 1990 Mar;144(3):285-9. Am J Dis Child. 1990. PMID: 2154925 Clinical Trial.

8

Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants.

Vesikari T, Clark HF, Offit PA, Dallas MJ, DiStefano DJ, Goveia MG, Ward RL, Schödel F, Karvonen A, Drummond JE, DiNubile MJ, Heaton PM. Vesikari T, et al. Vaccine. 2006 May 29;24(22):4821-9. doi: 10.1016/j.vaccine.2006.03.025. Epub 2006 Mar 31. Vaccine. 2006. PMID: 16621194 Clinical Trial.

9

Improved immunogenicity of oral D x RRV reassortant rotavirus vaccine by Lactobacillus casei GG.

Isolauri E, Joensuu J, Suomalainen H, Luomala M, Vesikari T. Isolauri E, et al. Among authors: vesikari t. Vaccine. 1995 Feb;13(3):310-2. doi: 10.1016/0264-410x(95)93319-5. Vaccine. 1995. PMID: 7631519 Clinical Trial.

10

Clinical trials of live oral rotavirus vaccines: the Finnish experience.

Vesikari T. Vesikari T. Vaccine. 1993;11(2):255-61. doi: 10.1016/0264-410x(93)90026-t. Vaccine. 1993. PMID: 8382419 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

403 results

Search Page

Filters